Structure-Based Design of Novel Dihydroalkoxybenzyloxopyrimidine Derivatives as Potent Nonnucleoside Inhibitors of the Human Immunodeficiency Virus Reverse Transcriptase
E. Sudbeck(Drug Discovery Laboratory (Norway)), Fatih M. Uckun(University of Southern California)
Cited by 47
Related Papers
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|914